Kincell Bio, a cell therapy contract development and manufacturing organization (CDMO), has announced a new multi-year partnership with a clinical-stage cell therapy company. The agreement will see Kincell Bio produce patient-specific batches of clinical-grade product at its Gainesville, Florida facility.
 
This new contract adds to Kincell Bio’s growing portfolio of cell therapy projects, solidifying its position as a trusted partner in the industry. The company’s GMP-ready facility and experienced team are well-equipped to support clients’ clinical development plans and bring innovative therapies to market.
 
“We’re delighted to welcome another client to our Gainesville facility,” said Bruce Thompson, PhD., CEO of Kincell Bio. “Our facility is GMP-ready, and our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”